Semaglutide
STEP 4
Novo Nordisk · Phase 3 · Completed · Enrollment 902
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Semaglutide | Obesity or overweight | n/r | 20 | Efficacy | -8.3% at week 20 |
| Placebo | Obesity or overweight | n/r | 20 | Efficacy | 6.5% at week 20 |
| Semaglutide 2.4 mg, in trial | Obesity or overweight | 2.4 mg | 20 | ITT | n/r |
| Placebo, in trial | Obesity or overweight | n/r | 20 | ITT | n/r |